Abstract
Advances in various fields were discussed in the reviews and original research articles published in 2019 in Current Pharmaceutical Design. Here, I review some of the major highlights for selected areas. A better understanding of disease mechanisms was a prominent recurrent theme and new therapeutic targets based on those mechanisms are highlighted here. Inflammation and oxidative stress are major features of many diseases, therefore, interventions to address these processes are reviewed. Although repurposing of old drugs occurred in several fields, drug targeting and drug delivery, especially of nanoparticles, also continues to be a major area of interest.
[1]
Tarr AJ, Liu X, Reed NS, Quan N. Kinetic characteristics of euflammation: the induction of controlled inflammation without overt sickness behavior. Brain Behav Immun 2014; 42: 96-108.
[2]
Witkowski JM, Bryl E, Fulop T. Should we try to alleviate the immunosenescence and inflammaging - why, how and to what extent? Curr Pharm Des 2019; 25(39): 4150-62.
[3]
Cammarata G, Duro G, Di Chiara T, Lo Curto A, Taverna S, Candore G. Circulating miRNAs in successful and unsuccessful aging. A mini-review. Curr Pharm Des 2019; 25(39): 4150-3.
[4]
Banks WA. The blood-brain barrier in neuroimmunology: tales of separation and assimilation. Brain Behav Immun 2015; 44: 1-8.
[6]
Otero-Losada M, Canepa L, Udovin L, et al. Long-term effects of hypoxia-reoxygenation on thioredoxins in rat central nervous system. Curr Pharm Des 2019; 25(39): 4168-74.
[7]
Gambino CM, Sasso BL, Bivona G, Agnello L, Ciaccio M. Aging and neuroinflammatory disorders: new biomarkers and therapeutic targets. Curr Pharm Des 2019.
[8]
Yuan Y, Wu C, Ling EA. Heterogeneity of microglia phenotypes: developmental, functional and some therapeutic considerations. Curr Pharm Des 2019; 25: 2375-93.
[9]
Varas R, Ortiz FC. Neuroinflammation in demyelinating diseases: oxidative stress as a modulator of glial cross-talk. Curr Pharm Des 2019; 25(45): 4755-62.
[10]
Ding Y, Wang R, Zhang J, et al. Potential regulation mechanisms of p-gp in the blood-brain barrier in hypoxia. Curr Pharm Des 2019; 25: 1041-51.
[12]
Yu C, Argyropoulos G, Zhang Y, Kastin AJ, Hsuchou H, Pan W. Neuroinflammation activates Mdr1b efflux transport through NFkappaB: promoter analysis in BBB endothelia. Cell Physiol Biochem 2008; 22: 745-56.
[13]
Yu C, Kastin AJ, Tu H, Waters S, Pan W. TNF activates P-glycoprotein in cerebral microvascular endothelial cells. Cell Physiol Biochem 2007; 20: 853-8.
[14]
Caruso G, Spampinato SF, Cardaci V, Caraci F, Sortino MA, Merlo S. Beta-amyloid and oxidative stress: perspectives in drug development. Curr Pharm Des 2019; 25(45): 4771-81.
[15]
Cavestro C, Ferrero M, Mandrino S, Di Tavi M, Rota E. Novelty in inflammation and immunomodulation in migraine. Curr Pharm Des 2019; 25: 2919-36.
[16]
Gao D, Yu H, Li B, Chen L, Li X, Gu W. Cisplatin toxicology: the role of pro-inflammatory cytokines and GABA transporters in cochlear spiral ganglion. Curr Pharm Des 2019; 25(45): 4820-6.
[17]
Bujan GE, Serra HA, Molina SJ, Guelman LR. Prevention of brain damage triggered by alcohol consumption during adolescence: focus on oxidative stress. Curr Pharm Des 2019; 25(45): 4782-90.
[18]
Flores-Bastias O, Gomez GI, Orellana JA, Karahanian E. Activation of melanocortin-4 receptor by a synthetic agonist inhibits ethanol-induced neuroinflammation in rats. Curr Pharm Des 2019; 25(45): 4799-805.
[19]
Kardani A, Soltani A, Sewell RDE, Shahrani M, Rafieian-Kopaei M. Neurotransmitter, antioxidant and anti-neuroinflammatory mechanistic potentials of herbal medicines in ameliorating autism spectrum disorder. Curr Pharm Des 2019; 25(41): 4421-9.
[20]
Anderson G. Integrating pathophysiology in migraine: role of the gut microbiome and melatonin. Curr Pharm Des 2019; 25: 3550-62.
[21]
Thorne RG, Pronk GJ, Padmanabhan V, Frey WH II. Delivery of insulin-like growth factor-1 to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004; 127: 481-96.
[22]
Banks WA, Kastin AJ, Komaki G, Arimura A. Passage of pituitary adenylate cyclase activating polypeptide 1-27 and pituitary adenylate cyclase activating polypeptide 1-38 across the blood-brain barrier. J Pharmacol Exp Ther 1993; 267: 690-6.
[23]
Nonaka N, Farr SA, Nakamachi T, et al. Intranasal administration of PACAP: uptake by brain and brain region targeting with cyclodextrins. Peptides 2012; 36(2): 168-75.
[24]
Rafe T, Shawon PA, Salem L, et al. Preventive role of resveratrol against inflammatory cytokines and related diseases. Curr Pharm Des 2019; 25: 1345-71.
[25]
Pourhanifeh MH, Shafabakhsh R, Reiter RJ, Asemi Z. The effect of resveratrol on neurodegenerative disorders: possible protective actions against autophagy, apoptosis, inflammation and oxidative stress. Curr Pharm Des 2019; 25: 2178-91.
[26]
Sun L, Ji S, Xing J. Inhibition of microRNA-155 alleviates neurological deficits following transient global ischemia and contribution of neuroinflammation and oxidative stress in the hippocampus. Curr Pharm Des 2019; 25(40): 4310-7.
[27]
Yan Y, Tong F, Chen J. Endogenous BMP-4/ROS/COX-2 Mediated IPC and resveratrol alleviated brain damage. Curr Pharm Des 2019; 25: 1030-9.
[28]
Shayesteh MRH, Haghi-Aminjan H, Mousavi MJ, Momtaz S, Abdollahi M. The protective mechanism of cannabidiol in cardiac injury: a systematic review of non-clinical studies. Curr Pharm Des 2019; 25: 2499-507.
[29]
Ishibashi T. Molecular hydrogen: new antioxidant and anti-inflammatory therapy for rheumatoid arthritis and related diseases. Curr Pharm Des 2013; 19: 6375-81.
[30]
Dohi K, Kraemer BC, Erickson MA, et al. Molecular hydrogen in drinking water protects against neurodegenerative changes induced by traumatic brain injury. PLoS One 2014; 24: 9. e108034
[31]
Ishibashi T. Therapeutic efficacy of molecular hydrogen: a new mechanistic insight. Curr Pharm Des 2019; 25: 946-55.
[32]
Katsiki N, Anagnostis P, Kotsa K, Goulis DG, Mikhailidis DP. Obesity, metabolic syndrome and the risk of microvascular complications in patients with diabetes mellitus. Curr Pharm Des 2019; 25: 2051-9.
[33]
Ctoi AF, Vodnar DC, Corina A, et al. Gut microbiota, obesity and bariatric surgery: current knowledge and future perspectives. Curr Pharm Des 2019; 25: 2038-50.
[34]
Femlak M, Gluba-Brzozka A, Franczyk B, Rysz J. Diabetes-induced alterations in HDL subfractions distribution. Curr Pharm Des 2019. In Press
[35]
Gouni-Berthold I, Berthold HK. Current options for the pharmacotherapy of obesity. Curr Pharm Des 2019; 25: 2019-32.
[36]
Pastor R, Tur JA. Liraglutide for the treatment of obesity: analyzing published reviews. Curr Pharm Des 2019; 25: 1783-90.
[37]
Zuo L, Wang J, Zhang N, Wang J. Pioglitazone therapy decreases bone mass density and increases fat mass: a meta-analysis. Curr Pharm Des 2019; 25: 3590-6.
[38]
Joksic G, Trickovic JF, Joksic I. Potential of gentiana lutea for the treatment of obesity-associated diseases. Curr Pharm Des 2019; 25: 2071-6.
[39]
Guo W, Gong X, Li M. Quercetin actions on lipid profiles in overweight and obese individuals: a systematic review and meta-analysis. Curr Pharm Des 2019; 25: 3087-95.
[40]
Tamtaji OR, Milajerdi A, Dadgostar E, et al. The effects of quercetin supplementation on blood pressures and endothelial function among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. Curr Pharm Des 2019; 25: 1372-84.
[41]
Zaric BL, Obradovic M, Sudar-Milovanovic E, Nedeljkovic J, Lazic V, Isenovic ER. Drug delivery systems for diabetes treatment. Curr Pharm Des 2019; 25: 166-73.
[42]
Rhea EM, Salameh TS, Banks WA. Routes for the delivery of insulin to the centeral nervous system: a comparative review. Exp Neurol 2019; 313: 10-5.
[43]
Khan S, Kamal MA. Wogonin alleviates hyperglycemia through increased glucose entry into cells Via AKT/GLUT4 pathway. Curr Pharm Des 2019; 25: 2602-6.
[44]
Usman B, Sharma N, Satija S, et al. Recent developments in alpha-glucosidase inhibitors for management of type-2 diabetes: an update. Curr Pharm Des 2019; 25: 2510-25.
[45]
Corina A, Abrudan MB, Nikolic D, et al. Effects of aging and diet on cardioprotection and cardiometabolic risk markers. Curr Pharm Des 2019; 25: 3704-14.
[46]
Frigerio B, Werba JP, Amato M, et al. Traditional risk factors are causally related to carotid intima-media thickness progression: inferences from observational cohort studies and interventional trials. Curr Pharm Des 2019.
[47]
Li J, Sun D, Li Y. Novel findings and therapeutic targets on cardioprotection of ischemia/ reperfusion injury in STEMI. Curr Pharm Des 2019; 25: 3726-39.
[48]
Veloso CD, Belew GD, Ferreira LL, et al. A mitochondrial approach to cardiovascular risk and disease. Curr Pharm Des 2019; 25: 3175-94.
[49]
Satta N, Frias MA, Vuilleumier N, Pagano S. Humoral immunity against HDL particle: a new perspective in cardiovascular diseases? Curr Pharm Des 2019; 25: 3128-46.
[50]
Zheng H, Zeng Z, Wen H, et al. Application of genome-wide association studies in coronary artery disease. Curr Pharm Des 2019.
[51]
Butta C, Tuttolomondo A, Petrantoni R, Miceli G, Pinto A. Old and new drugs for treatment of advanced heart failure. Curr Pharm Des 2019. In Press
[52]
Yamagata K. Polyphenols regulate endothelial functions and reduce the risk of cardiovascular disease. Curr Pharm Des 2019; 25: 2443-58.
[53]
Jiang H, Zhang B, Jia D, Yang W, Sun A, Ge J. Insights from exercise-induced cardioprotection-from clinical application to basic research. Curr Pharm Des 2019; 25: 3751-61.
[54]
Allen J, Sun Y, Woods JA. Exercise and the regulation of inflammatory responses. Prog Mol Biol Transl Sci 2015; 135: 337-54.
[56]
Obradovic M, Zafirovic S, Soskic S, et al. Effects of IGF-1 on the cardiovascular system. Curr Pharm Des 2019; 25: 3715-25.
[57]
Sun N, Li D, Chen X, et al. New applications of oleanolic acid and its derivatives as cardioprotective agents: a review of their therapeutic perspectives. Curr Pharm Des 2019; 25: 3740-50.
[58]
Bartman CM, Eckle T. Circadian-hypoxia link and its potential for treatment of cardiovascular disease. Curr Pharm Des 2019; 25: 1075-90.
[59]
Patras L, Banciu M. Intercellular crosstalk via extracellular vesicles in tumor milieu as emerging therapies for cancer progression. Curr Pharm Des 2019; 25: 1980-2006.
[60]
Li M, Jiang M, Meng J, Tao L. Exosomescarriers of pro-fibrotic signals and therapeutic targets in fibrosis. Curr Pharm Des 2019; 25(42): 4496-509.
[61]
Vecchie A, Montecucco F, Carbone F, Dallegri F, Bonaventura A. Diabetes and vascular disease: is it all about glycemia? Curr Pharm Des 2019; 25: 3112-27.
[62]
Park EJ, Appiah MG, Myint PK, Gaowa A, Kawamoto E, Shimaoka M. Exosomes in sepsis and inflammatory tissue injury. Curr Pharm Des 2019; 25(42): 4486-95.
[63]
Tu C, He J, Chen R, Li Z. The emerging role of exosomal non-coding RNAs in musculoskeletal diseases. Curr Pharm Des 2019; 25(42): 4523-35.
[65]
Zaheer U, Faheem M, Qadri I, et al. Expression profile of MicroRNA: an emerging hallmark of cancer. Curr Pharm Des 2019; 25(42): 642-53.
[66]
Kluszczynska K, Czernek L, Cypryk W, Peczek L, Duchler M. Methods for the determination of the purity of exosomes. Curr Pharm Des 2019; 25(42): 4464-85.
[67]
Surman M, Drozdz A, Stepien E, Przybylo M. Extracellular vesicles as drug delivery systems - methods of production and potential therapeutic applications. Curr Pharm Des 2019; 25(2): 132-54.
[68]
Upadhya D, Shetty AK. Extracellular vesicles as therapeutics for brain injury and disease. Curr Pharm Des 2019; 25(33): 3500-5.
[69]
Haney MJ, Klyachko NL, Zhao Y, et al. Exosomes as drug delivery vehicles for Parkinson’s disease therapy. J of Control Release 2015; 207: 18-30.
[70]
Yuan D, Zhao Y, Banks WA, et al. Macrophage exosomes as natural nanocarriers for protein delivery to inflamed brain. Biomaterials 2017; 142: 1-12.
[71]
Longoni B, Fasciani I, Kolachalam S, et al. Neurotoxic and neuroprotective role of exosomes in parkinson’s disease. Curr Pharm Des 2019; 25(42): 4510-22.
[72]
Matsumoto J, Stewart T, Sheng L, et al. Transmission of alpha-synuclein-containing erythrocyte-derived extracellular vesicles across the blood-brain barrier via adsorptive mediated transcytosis: another mechanism for initiation and progression of Parkinson’s disease. Acta Neurologica Communications 2017; 5: 71.
[73]
Shi M, Kovac A, Korff A, et al. CNS tau efflux via exosomes is likey decreased in parkinson disease but not in alzheimer disease. Alzheimers & Dement 2016; 12: 1125-31.
[74]
Nakashima S, Nacher JC, Song J, Akutsu T. An overview of bioinformatics methods for analyzing autism spectrum disorders. Curr Pharm Des 2019; 25(43): 4552-9.
[75]
Beversdorf DQ, Stevens HE, Margolis KG, Van de Water J. Prenatal stress and maternal immune dysregulation in autism spectrum disorders- potential points for intervention. Curr Pharm Des 2019; 25(41): 4331-43.
[76]
Alzghoul L. Role of vitamin D in autism spectrum disorder. Curr Pharm Des 2019; 25(41): 4357-67.
[77]
Banks WA. A vagina monologue: mom’s stress, bugs, and baby’s brain. Endocrinology 2015; 156: 3066-8.
[78]
Jasarevic E, Howerton CL, Howard CD, Bale TL. Alterations in the vaginal microbiome by maternal stress are associated with metabolic reprogramming of the offspring gut and brain. Endocrinology 2015; 156: 3265-76.
[79]
Seo M, Anderson G. Gut-amygdala interactions in autism spectrum disorders: developmental roles via regulating mitochondria, exosomes, immunity and microRNAs. Curr Pharm Des 2019; 25(41): 4344-56.
[80]
Pinato L, Spilla CSG, Markus RP, da Silveira Cruz-Machado S. Dysregulation of circadian rhythms in autism spectrum disorders. Curr Pharm Des 2019; 25(41): 4379-93.
[81]
Vasu MM, Sumitha PS, Rahna P, Thanseem I, Anitha A. MicroRNAs in autism spectrum disorders. Curr Pharm Des 2019; 25(41): 4368-78.
[82]
Maes M, Anderson G, Betancort Medina SR, Seo M, Ojala JO. Integrating autism spectrum disorder pathophysiology: mitochondria, vitamin A, CD38, oxytocin, serotonin and melatonergic alterations in the placenta and gut. Curr Pharm Des 2019; 25(41): 4405-20.
[83]
Santos G, Borges JMP, Avila-Rodriguez M, et al. Copper and neurotoxicity in autism spectrum disorder. Curr Pharm Des 2019; 25(45): 4747-54.
[84]
Pacheva I, Ivanov I. Targeted biomedical treatment for autism spectrum disorders. Curr Pharm Des 2019; 25(41): 4430-53.
[85]
Ruggieri V, Gomez JLC, Martinez MM, Arberas C. Aging and autism: understanding, intervention, and proposals to improve quality of life. Curr Pharm Des 2019; 25(41): 4454-61.
[86]
Lee Y, Lee BH, Yip W, Chou P, Yip BS. Neurofilament proteins as prognostic biomarkers in neurological disorders. Curr Pharm Des 2019; 25(43): 4560-9.
[87]
Zhang L, Li X, Wang D, et al. Risk factors of recurrent ischemic events after acute noncardiogenic ischemic stroke. Curr Pharm Des 2019; 25(45): 4827-34.
[88]
Qi J, Liu C, Chen L, Chen J. Postoperative serum albumin decrease independently predicts delirium in elderly subjects after total joint arthroplasty. Curr Pharm Des 2019. In Press
[89]
Zhunina OA, Yabbarov NG, Grechko AV, Yet SF, Sobenin IA, Orekhov AN. Neurodegenerative diseases associated with mitochondrial DNA mutations. Curr Pharm Des 2019. In Press
[90]
Wang H. Anti-NMDA receptor encephalitis, vaccination and viruses. Curr Pharm Des 2019; 25(43): 4579-88.
[91]
Gigliobianco MR, Di Martino P, Deng S, Casadidio C, Censi R. New advanced strategies for the treatment of lysosomal diseases affecting the central nervous system. Curr Pharm Des 2019; 25: 1933-50.
[92]
Taliyan R, Chandran SK, Kakoty V. Therapeutic approaches to alzheimer’s type of dementia: a focus on FGF21 mediated neuroprotection. Curr Pharm Des 2019; 25: 2555-68.
[93]
Werner FM, Covenas R. Neural networks in generalized epilepsy and novel antiepileptic drugs. Curr Pharm Des 2019; 25: 396-400.
[94]
Gondim BLC, Catarino JDS, Dias de Sousa MA, et al. Nanoparticle-mediated drug delivery: blood-brain barrier as the main obstacle to treating infectious diseases in CNS. Curr Pharm Des 2019; 25(37): 3983-96.
[95]
Banks WA, Engelke K, Hansen KM, Bullock KM, Calias P. Modest blood-brain barrier permeability of the cyclodextrin kleptose: modification by efflux and luminal surface binding. J Pharmacol Exp Ther 2019; 371: 121-9.
[96]
Raut SY, Manne ASN, Kalthur G, Jain S, Mutalik S. Cyclodextrins as carriers in targeted delivery of therapeutic agents: focused review on traditional and inimitable applications. Curr Pharm Des 2019; 25: 444-54.
[97]
Calias P. 2-Hydroxypropyl-Beta-cyclodextrins and the blood-brain barrier: considerations for niemann-pick disease type C1. Curr Pharm Des 2017; 23: 6231-8.
[98]
Tang H, Zhu Q, Li W, et al. Neurophysiology and treatment of disorders of consciousness induced by traumatic brain injury: orexin signaling as a potential therapeutic target. Curr Pharm Des 2019; 25(39): 4208-20.
Related Journals
Current Drug Safety
Current Medicinal Chemistry
Current Neuropharmacology
Current Pharmaceutical Analysis
Current Topics in Medicinal Chemistry
Current Vascular Pharmacology
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
CNS & Neurological Disorders - Drug Targets
Related Books
New Findings from Natural Substances
Mitochondrial DNA and the Immuno-inflammatory Response: New Frontiers to Control Specific Microbial Diseases
Pharmaceutical Chemistry and Production: An Introductory Textbook
Evidence-Based Research in Ayurveda against COVID-19 in Compliance with Standardized Protocols and Practices
Frontiers in Clinical Drug Research – Anti Allergy Agents
Pharmaceuticals for Targeting Coronaviruses
Medical Applications of Beta-Glucan
Nanotechnology Driven Herbal Medicine for Burns: From Concept to Application
Postbiotics: Science, Technology and Applications
Frontiers in Inflammation
Article Metrics
15
3